-
Je něco špatně v tomto záznamu ?
Quantification of extracellular DNA using hypermethylated RASSF1A, SRY, and GLO sequences--evaluation of diagnostic possibilities for predicting placental insufficiency
I. Hromadnikova, L. Zejskova, K. Kotlabova, T. Jancuskova, J. Doucha, K. Dlouha, L. Krofta, JE. Jirasek, R. Vlk,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
PubMed
20235876
DOI
10.1089/dna.2009.0971
Knihovny.cz E-zdroje
- MeSH
- beta-globiny genetika metabolismus MeSH
- časové faktory MeSH
- DNA genetika MeSH
- extracelulární prostor genetika MeSH
- genetické markery genetika MeSH
- lidé MeSH
- matky MeSH
- metylace DNA MeSH
- nádorové supresorové proteiny krev genetika MeSH
- placentární insuficience krev diagnóza genetika MeSH
- plod cytologie MeSH
- protein oblasti určující pohlaví na chromozomu Y krev genetika MeSH
- riziko MeSH
- studie případů a kontrol MeSH
- těhotenství MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- těhotenství MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
This study evaluated quantification of fetal extracellular DNA in maternal plasma for differentiation between cases at risk of onset of placental-insufficiency-related complications and normal pregnancies. Using real-time polymerase chain reaction, fetal (sex-determining region Y [SRY] and hypermethylated RASSF1A sequence) and total (beta-globin [GLO] gene) extracellular DNA was examined in 70 normal pregnancies, 18 at risk of placental-insufficiency-related pregnancy complications, 24 preeclampsia with or without (w or w/o) intrauterine growth retardation (IUGR) (median 34.0 week), and 11 IUGR (median 28.5 week). IUGR was diagnosed when estimated fetal weight was below the 10th percentile for evaluated gestational age. Although increased levels of extracellular DNA were detected in pregnancies with preeclampsia w or w/o IUGR relative to controls (RASSF1A, p < 0.001; SRY, p = 0.009; GLO, p < 0.001), quantities of fetal extracellular DNA in IUGR were not statistically significant (RASSF1A, p = 0.21; SRY, p = 0.2). RASSF1A, SRY, and GLO achieved 93.1%, 93.6%, and 92.1% accuracy for differentiation between normal pregnancy and preeclampsia w or w/o IUGR. Lower sensitivity was observed for pregnancies with onset of IUGR (RASSF1A, 60.0%; SRY, 80.0%; GLO, 72.7%), but did not influence final accuracy (RASSF1A, 91.6%; SRY, 92.5%; GLO, 89.5%). Among 18 patients at risk, 8 pregnancies involving 3 female and 5 male fetuses developed preeclampsia (n = 4), IUGR (n = 3), and chronic placentopathy causing hypoxia (n = 1). Elevation of extracellular DNA was demonstrated in 3/5 (SRY), 1/8 (hypermethylated RASSF1A), and 4/8 (GLO) patients at the earliest 26 weeks and at the latest 2 weeks before the onset of symptoms. These data indicate that fetal and total extracellular DNA concentrations can be significantly elevated in plasma of patients who later developed placental-insufficiency-related pregnancy complications. However, this is strongly individualized, and not a rule for all cases, and probably depends on the actual occurrence of excessive placental trophoblast apoptosis.
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc12025867
- 003
- CZ-PrNML
- 005
- 20121207094552.0
- 007
- ta
- 008
- 120817s2010 xxu f 000 0#eng||
- 009
- AR
- 024 7_
- $a 10.1089/dna.2009.0971 $2 doi
- 035 __
- $a (PubMed)20235876
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Hromadnikova, Ilona $u Department of Molecular Biology and Cell Pathology, Third Faculty of Medicine, Charles University, Prague, Czech Republic. ilona.hromadnikova@lf3.cuni.cz
- 245 10
- $a Quantification of extracellular DNA using hypermethylated RASSF1A, SRY, and GLO sequences--evaluation of diagnostic possibilities for predicting placental insufficiency / $c I. Hromadnikova, L. Zejskova, K. Kotlabova, T. Jancuskova, J. Doucha, K. Dlouha, L. Krofta, JE. Jirasek, R. Vlk,
- 520 9_
- $a This study evaluated quantification of fetal extracellular DNA in maternal plasma for differentiation between cases at risk of onset of placental-insufficiency-related complications and normal pregnancies. Using real-time polymerase chain reaction, fetal (sex-determining region Y [SRY] and hypermethylated RASSF1A sequence) and total (beta-globin [GLO] gene) extracellular DNA was examined in 70 normal pregnancies, 18 at risk of placental-insufficiency-related pregnancy complications, 24 preeclampsia with or without (w or w/o) intrauterine growth retardation (IUGR) (median 34.0 week), and 11 IUGR (median 28.5 week). IUGR was diagnosed when estimated fetal weight was below the 10th percentile for evaluated gestational age. Although increased levels of extracellular DNA were detected in pregnancies with preeclampsia w or w/o IUGR relative to controls (RASSF1A, p < 0.001; SRY, p = 0.009; GLO, p < 0.001), quantities of fetal extracellular DNA in IUGR were not statistically significant (RASSF1A, p = 0.21; SRY, p = 0.2). RASSF1A, SRY, and GLO achieved 93.1%, 93.6%, and 92.1% accuracy for differentiation between normal pregnancy and preeclampsia w or w/o IUGR. Lower sensitivity was observed for pregnancies with onset of IUGR (RASSF1A, 60.0%; SRY, 80.0%; GLO, 72.7%), but did not influence final accuracy (RASSF1A, 91.6%; SRY, 92.5%; GLO, 89.5%). Among 18 patients at risk, 8 pregnancies involving 3 female and 5 male fetuses developed preeclampsia (n = 4), IUGR (n = 3), and chronic placentopathy causing hypoxia (n = 1). Elevation of extracellular DNA was demonstrated in 3/5 (SRY), 1/8 (hypermethylated RASSF1A), and 4/8 (GLO) patients at the earliest 26 weeks and at the latest 2 weeks before the onset of symptoms. These data indicate that fetal and total extracellular DNA concentrations can be significantly elevated in plasma of patients who later developed placental-insufficiency-related pregnancy complications. However, this is strongly individualized, and not a rule for all cases, and probably depends on the actual occurrence of excessive placental trophoblast apoptosis.
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a DNA $x genetika $7 D004247
- 650 _2
- $a metylace DNA $7 D019175
- 650 _2
- $a extracelulární prostor $x genetika $7 D005110
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a plod $x cytologie $7 D005333
- 650 _2
- $a genetické markery $x genetika $7 D005819
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a matky $7 D009035
- 650 _2
- $a placentární insuficience $x krev $x diagnóza $x genetika $7 D010927
- 650 _2
- $a těhotenství $7 D011247
- 650 _2
- $a riziko $7 D012306
- 650 _2
- $a protein oblasti určující pohlaví na chromozomu Y $x krev $x genetika $7 D051876
- 650 _2
- $a časové faktory $7 D013997
- 650 _2
- $a nádorové supresorové proteiny $x krev $x genetika $7 D025521
- 650 _2
- $a beta-globiny $x genetika $x metabolismus $7 D055544
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Zejskova, Lenka
- 700 1_
- $a Kotlabova, Katerina
- 700 1_
- $a Jancuskova, Tereza
- 700 1_
- $a Doucha, Jindrich
- 700 1_
- $a Dlouha, Klara
- 700 1_
- $a Krofta, Ladislav
- 700 1_
- $a Jirasek, Jan E
- 700 1_
- $a Vlk, Radovan
- 773 0_
- $w MED00007256 $t DNA and cell biology $x 1557-7430 $g Roč. 29, č. 6 (2010), s. 295-301
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/20235876 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y m
- 990 __
- $a 20120817 $b ABA008
- 991 __
- $a 20121207094626 $b ABA008
- 999 __
- $a ok $b bmc $g 947909 $s 783213
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2010 $b 29 $c 6 $d 295-301 $i 1557-7430 $m DNA and cell biology $n DNA Cell Biol $x MED00007256
- LZP __
- $a Pubmed-20120817/10/03